Viking's Dual Agonist Drug Shows Potential As It Moves Through Trial Process A much smaller firm than Eli Lilly, Viking Therapeutics Inc
Thats the story I want to share with you
The peptide has shown substantial therapeutic potential in experimental models of inflammatory bowel disease, gastric ulceration, and various gastrointestinal inflammatory conditions
Interfering with the effect of microbial metabolites on anti-tumour immunity can be achieved using different strategies, each with its own advantages and limitations
Fernandez-Fernandez B, Sarafidis P, Kanbay M, et al
In the pancreas, GLP-1 receptor agonists promote more effective insulin secretion after a meal, she adds